Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes:: the ADDITION‐Europe trial

E. M. Dalsgaard; A. Sandbæk; S. J. Griffin; G. E.H.M. Rutten; K. Khunti; M. J. Davies; G. J. Irving; R. C. Vos; D. R. Webb; N. J. Wareham; D. R. Witte

doi:10.1111/dme.14342

Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial

E. M. Dalsgaard^*, A. Sandbæk, S. J. Griffin, G. E.H.M. Rutten, K. Khunti, M. J. Davies, G. J. Irving, R. C. Vos, D. R. Webb, N. J. Wareham, D. R. Witte

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aims: To present the longer-term impact of multifactorial treatment of type 2 diabetes on self-reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction at 10-year follow up of the ADDITION-Europe trial. Methods: The ADDITION-Europe trial enrolled 3057 individuals with screen-detected type 2 diabetes from four centres [Denmark, the UK (Cambridge and Leicester) and the Netherlands], between 2001 and 2006. Participants were randomized at general practice level to intensive treatment or to routine care. The trial ended in 2009 and a 10-year follow-up was performed at the end of 2014. We measured self-reported health status (36-item Short-Form Health Survey and EQ-5D), diabetes-specific quality of life (Audit of Diabetes-Dependent Quality of Life questionnaire), and diabetes treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire) at different time points during the study period. A mixed-effects model was applied to estimate the effect of intensive treatment (intention-to-treat analyses) on patient-reported outcome measures for each centre. Centre-specific estimates were pooled using a fixed effects meta-analysis. Results: There was no difference in patient-reported outcome measures between the routine care and intensive treatment arms in this 10-year follow-up study [EQ-5D: –0.01 (95% CI –0.03, 0.01); Physical Composite Score (36-item Short-Form Health Survey): –0.27 (95% CI –1.11, 0.57), Audit of Diabetes-Dependent Quality of Life questionnaire: –0.01 (95% CI –0.11, 0.10); and Diabetes Treatment Satisfaction Questionnaire: –0.20 (95% CI –0.70, 0.29)]. Conclusions: Intensive, multifactorial treatment of individuals with screen-detected type 2 diabetes did not affect self-reported health status, diabetes-specific quality of life, or diabetes treatment satisfaction at 10-year follow-up compared to routine care.

Original language	English
Pages (from-to)	1509-1518
Number of pages	10
Journal	Diabetic Medicine
Volume	37
Issue number	9
DOIs	https://doi.org/10.1111/dme.14342
Publication status	Published - Sept 2020

Access to Document

10.1111/dme.14342

https://onlinelibrary.wiley.com/doi/10.1111/dme.14342Licence: Unspecified

Cite this

Dalsgaard, E. M., Sandbæk, A., Griffin, S. J., Rutten, G. E. H. M., Khunti, K., Davies, M. J., Irving, G. J., Vos, R. C., Webb, D. R., Wareham, N. J., & Witte, D. R. (2020). Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial. Diabetic Medicine, 37(9), 1509-1518. https://doi.org/10.1111/dme.14342

@article{a4236b82ee694c339200f8858c0e0e7d,

title = "Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes:: the ADDITION‐Europe trial",

abstract = "Aims: To present the longer-term impact of multifactorial treatment of type 2 diabetes on self-reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction at 10-year follow up of the ADDITION-Europe trial. Methods: The ADDITION-Europe trial enrolled 3057 individuals with screen-detected type 2 diabetes from four centres [Denmark, the UK (Cambridge and Leicester) and the Netherlands], between 2001 and 2006. Participants were randomized at general practice level to intensive treatment or to routine care. The trial ended in 2009 and a 10-year follow-up was performed at the end of 2014. We measured self-reported health status (36-item Short-Form Health Survey and EQ-5D), diabetes-specific quality of life (Audit of Diabetes-Dependent Quality of Life questionnaire), and diabetes treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire) at different time points during the study period. A mixed-effects model was applied to estimate the effect of intensive treatment (intention-to-treat analyses) on patient-reported outcome measures for each centre. Centre-specific estimates were pooled using a fixed effects meta-analysis. Results: There was no difference in patient-reported outcome measures between the routine care and intensive treatment arms in this 10-year follow-up study [EQ-5D: –0.01 (95% CI –0.03, 0.01); Physical Composite Score (36-item Short-Form Health Survey): –0.27 (95% CI –1.11, 0.57), Audit of Diabetes-Dependent Quality of Life questionnaire: –0.01 (95% CI –0.11, 0.10); and Diabetes Treatment Satisfaction Questionnaire: –0.20 (95% CI –0.70, 0.29)]. Conclusions: Intensive, multifactorial treatment of individuals with screen-detected type 2 diabetes did not affect self-reported health status, diabetes-specific quality of life, or diabetes treatment satisfaction at 10-year follow-up compared to routine care.",

author = "Dalsgaard, {E. M.} and A. Sandb{\ae}k and Griffin, {S. J.} and Rutten, {G. E.H.M.} and K. Khunti and Davies, {M. J.} and Irving, {G. J.} and Vos, {R. C.} and Webb, {D. R.} and Wareham, {N. J.} and Witte, {D. R.}",

note = "{\textcopyright} 2020 Diabetes UK.",

year = "2020",

month = sep,

doi = "10.1111/dme.14342",

language = "English",

volume = "37",

pages = "1509--1518",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "9",

}

Dalsgaard, EM, Sandbæk, A, Griffin, SJ, Rutten, GEHM, Khunti, K, Davies, MJ, Irving, GJ, Vos, RC, Webb, DR, Wareham, NJ & Witte, DR 2020, 'Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial', Diabetic Medicine, vol. 37, no. 9, pp. 1509-1518. https://doi.org/10.1111/dme.14342

Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial. / Dalsgaard, E. M.; Sandbæk, A.; Griffin, S. J. et al.
In: Diabetic Medicine, Vol. 37, No. 9, 09.2020, p. 1509-1518.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes:

T2 - the ADDITION‐Europe trial

AU - Dalsgaard, E. M.

AU - Sandbæk, A.

AU - Griffin, S. J.

AU - Rutten, G. E.H.M.

AU - Khunti, K.

AU - Davies, M. J.

AU - Irving, G. J.

AU - Vos, R. C.

AU - Webb, D. R.

AU - Wareham, N. J.

AU - Witte, D. R.

PY - 2020/9

Y1 - 2020/9

N2 - Aims: To present the longer-term impact of multifactorial treatment of type 2 diabetes on self-reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction at 10-year follow up of the ADDITION-Europe trial. Methods: The ADDITION-Europe trial enrolled 3057 individuals with screen-detected type 2 diabetes from four centres [Denmark, the UK (Cambridge and Leicester) and the Netherlands], between 2001 and 2006. Participants were randomized at general practice level to intensive treatment or to routine care. The trial ended in 2009 and a 10-year follow-up was performed at the end of 2014. We measured self-reported health status (36-item Short-Form Health Survey and EQ-5D), diabetes-specific quality of life (Audit of Diabetes-Dependent Quality of Life questionnaire), and diabetes treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire) at different time points during the study period. A mixed-effects model was applied to estimate the effect of intensive treatment (intention-to-treat analyses) on patient-reported outcome measures for each centre. Centre-specific estimates were pooled using a fixed effects meta-analysis. Results: There was no difference in patient-reported outcome measures between the routine care and intensive treatment arms in this 10-year follow-up study [EQ-5D: –0.01 (95% CI –0.03, 0.01); Physical Composite Score (36-item Short-Form Health Survey): –0.27 (95% CI –1.11, 0.57), Audit of Diabetes-Dependent Quality of Life questionnaire: –0.01 (95% CI –0.11, 0.10); and Diabetes Treatment Satisfaction Questionnaire: –0.20 (95% CI –0.70, 0.29)]. Conclusions: Intensive, multifactorial treatment of individuals with screen-detected type 2 diabetes did not affect self-reported health status, diabetes-specific quality of life, or diabetes treatment satisfaction at 10-year follow-up compared to routine care.

AB - Aims: To present the longer-term impact of multifactorial treatment of type 2 diabetes on self-reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction at 10-year follow up of the ADDITION-Europe trial. Methods: The ADDITION-Europe trial enrolled 3057 individuals with screen-detected type 2 diabetes from four centres [Denmark, the UK (Cambridge and Leicester) and the Netherlands], between 2001 and 2006. Participants were randomized at general practice level to intensive treatment or to routine care. The trial ended in 2009 and a 10-year follow-up was performed at the end of 2014. We measured self-reported health status (36-item Short-Form Health Survey and EQ-5D), diabetes-specific quality of life (Audit of Diabetes-Dependent Quality of Life questionnaire), and diabetes treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire) at different time points during the study period. A mixed-effects model was applied to estimate the effect of intensive treatment (intention-to-treat analyses) on patient-reported outcome measures for each centre. Centre-specific estimates were pooled using a fixed effects meta-analysis. Results: There was no difference in patient-reported outcome measures between the routine care and intensive treatment arms in this 10-year follow-up study [EQ-5D: –0.01 (95% CI –0.03, 0.01); Physical Composite Score (36-item Short-Form Health Survey): –0.27 (95% CI –1.11, 0.57), Audit of Diabetes-Dependent Quality of Life questionnaire: –0.01 (95% CI –0.11, 0.10); and Diabetes Treatment Satisfaction Questionnaire: –0.20 (95% CI –0.70, 0.29)]. Conclusions: Intensive, multifactorial treatment of individuals with screen-detected type 2 diabetes did not affect self-reported health status, diabetes-specific quality of life, or diabetes treatment satisfaction at 10-year follow-up compared to routine care.

UR - http://www.scopus.com/inward/record.url?scp=85089100609&partnerID=8YFLogxK

U2 - 10.1111/dme.14342

DO - 10.1111/dme.14342

M3 - Article

C2 - 32530523

AN - SCOPUS:85089100609

SN - 0742-3071

VL - 37

SP - 1509

EP - 1518

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 9

ER -

Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this